Lior ShaltielCEO at NurExone BiologicSpeaker
Profile
Dr. Lior Shaltiel is an awarded executive and scientist with a wealth of multidisciplinary international experience, specializing in innovative drug delivery systems. Since 2021, serving as the CEO and Director at NurExone Biologic Inc., an Canadian-Israeli biopharmaceutical company (TSXV:NRX) (OTCQB: NRXBF) at the forefront of utilizing advanced exosome technologies for the treatment of Spinal Cord Injury and CNS indications through minimally invasive administration.
In 2015, Dr. Shaltiel founded and currently leads as the Academic Head of the BioMed-MBA program at the Hebrew University Business School (HUBS), where he bridges academic knowledge with entrepreneurial success. With a strong background in the industry, Dr. Shaltiel leverages his expertise to seize investment opportunities. Recently, he assumed the role of Co-Chairman of the MedTech division at the Israeli Association of Engineers, further solidifying his commitment to innovation and advancement in the field and the ecosystem.
Agenda Sessions
Unlocking the Regenerative Potential of Exosomes: From Bioprocess Development to Advanced Drug Delivery Platform
, 11:35View SessionPanel Discussion: Beyond AAV- Non-Viral and Novel Delivery Systems – The Future of In Vivo Delivery Systems
, 12:05View Session